Net Sales of $83.4 Million in the Third Quarter
Net Income of $5.6 Million, with GAAP EPS of $0.11
Adjusted EBITDA1 of $14.4 Million, or $0.28 per Diluted Share
Record Revenue of $270.5 Million in the First Three
Former STAAR Executive and Ophthalmic Entrepreneur Returns to Lead Commercial Business in the Asia Pacific Region, Excluding China
Appointment Reflects STAAR’s Strategy to Localize Senior Commercial Leadership in One
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ:STAA) concerning possible breaches of fiduciary duties. If you are a
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a
Accomplished Ophthalmic Industry Executive and Clinician to Help Advance STAAR’s Strategic Partnerships, Innovation Opportunities, and Multi-Product Platform Strategy
STAAR Surgical Company ("STAAR" or the
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ:STAA) concerning possible breaches of fiduciary duties. If you are a
Shows 80% of Consumers Want to be Free of Glasses and Contacts, 58% Want a Reversible Option, and 59% Are Opposed to Laser Correction
Safety Concerns and Procedure Fears Outrank Affordability as Primary Barriers to
The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market
STAAR Surgical Company ("STAAR" or the
Net Sales of $93.5 million, up 111% Y/Y
Net Income of $8.1 million, with GAAP EPS of $0.16
Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share
Earnings Call and Webcast Today at 5:30 PM Eastern
STAAR
Deborah Andrews appointed Executive Vice President and Chief Financial Officer
STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate
